Investigating heart health issues in cancer patients treated with immunotherapy
Long-Term Cardiovascular Sequelae of Cancer Immunotherapies
This study is looking at how certain cancer treatments called immune checkpoint inhibitors might affect heart health in cancer survivors, helping us understand any long-term heart issues they might face.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-11138699 on NIH RePORTER |
What this research studies
This research focuses on understanding the long-term heart health problems that may arise in cancer survivors who have received immune checkpoint inhibitors (ICIs), a type of immunotherapy. The study will utilize both animal models and data from cancer survivors to explore how these therapies can lead to conditions like myocarditis and vasculitis. By examining the immune responses and cardiac health in these patients, the research aims to identify potential risks and mechanisms that contribute to cardiovascular complications after cancer treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research include cancer survivors who have undergone treatment with immune checkpoint inhibitors.
Not a fit: Patients who have not received immunotherapy or those without a history of cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved monitoring and management strategies for heart health in cancer survivors treated with immunotherapy.
How similar studies have performed: Previous research has indicated potential cardiovascular risks associated with immunotherapy, suggesting that this area of investigation is both relevant and necessary.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Moslehi, Javid J — University of California, San Francisco
- Study coordinator: Moslehi, Javid J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.